Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million ...

Haleon said in a prospectus filed earlier this week that it could face "possible liabilities" connected with OTC Zantac, although it is in the midst of indemnity negotiations with GSK and Pfizer ...

Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer ...

Based in the United Kingdom, Haleon makes consumer health care products, including Advil, Centrum Multivitamin and Aquafresh ...

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.

The UK-based consumer healthcare company will be modernizing its facility along Brook Road, where it conducts R&D for such ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Pfizer sold shares of Haleon last year, including a £2.4 billion overnight sale in the autumn. Haleon was formed in 2022 from a combination of GSK Plc and Pfizer’s consumer-health units.

(Sharecast News) - Pfizer has further reduced its holding in Haleon, it was confirmed on Wednesday ... among others - was originally part of pharmaceuticals firm GSK. It was formed through ...

Haleon was formed in 2019 as a joint venture of Pfizer and GSK PLC’s consumer health assets. It was listed on the London stock market in July 2022, with Pfizer retaining a 32% stake which it has ...

The sale represents nearly 7.7% of the issued share capital of Haleon, which was created by the merger of GSK and Pfizer's consumer healthcare businesses in 2019. It was spun off from the British ...